Dendreon, the Seattle biotech company developing an immune-boosting treatment for cancer, said today it finished ended 2008 with $108.5 million in cash and investments. The company (NASDAQ: [[ticker:DNDN]]) didn’t provide a financial forecast for how much of that it plans to spend in 2009. Dendreon is awaiting final results next month from a trial of 500 men that will determine whether its drug, sipuleucel-T (Provenge) is able to help men with terminal prostate cancer to live longer.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
